Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Gliosarcoma: early-phase trial registry
6 of 35 indexed Gliosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #435 of 28,707 conditions by registered trial count.
35 US clinical trials · 6 currently recruiting · #435 of 28,707 conditions by registered trial count
Gliosarcoma: 35 US clinical trials tracked, 6 recruiting.
Gliosarcoma is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 7 of these trials.
Enrollment posture brief
Registry condition gliosarcoma
OPEN 6 | RECR 17% | LATE 1 | EARLY 32 | RANK #435 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Stage IVB Lung Cancer AJCC v8 (17% recruiting · 35 trials)
Gliosarcoma lists 6 open slots (17% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Gliosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Gliosarcoma is recruiting below its size-band peers.
6 of 35 indexed trials (17.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Gliosarcoma research.
National Cancer Institute (NCI) accounts for 7 of 35 trials (20%). 24 distinct sponsors appear on at least one study for this condition label.
-
Most Gliosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 35 trials that report a genuine target (sentinel values excluded). 27 of those (77.1%) plan for fewer than 100 participants.
-
Gliosarcoma research is mostly interventional.
34 interventional and 1 observational studies make up this index (97.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
35 total, page 1 of 1
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Baptist Health South Florida
NCT05756985
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
NCT06934889
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
NCT04555577
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
NCT05084430
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
NCT05864534
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT05698524
Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT02152982
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NRG Oncology
NCT05095376
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ECOG-ACRIN Cancer Research Group
NCT03115333
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
NCT01903330
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
NCT02455557
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
Mayo Clinic
NCT03197506
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
NCT04817254
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
NCT04216329
Natural Progesterone for the Treatment of Recurrent Glioblastoma
Emory University
NCT05091866
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
National Cancer Institute (NCI)
NCT01609790
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
Celldex Therapeutics
NCT01498328
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Duke University
NCT00597402
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT00995007
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Annick Desjardins
NCT00613132
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
University of California, San Francisco
NCT00525525
Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
Katy Peters
NCT00610571
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Duke University
NCT00611325
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
NCT01149850
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Katy Peters
NCT00979017
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
NCT00612651
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT01837862
AMG 102 and Avastin for Recurrent Malignant Glioma
Katy Peters
NCT01113398
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT02101905
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
NCT00165477
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Seema Nagpal
NCT03020602
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
NCT00031083
GW572016 to Treat Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
NCT00107003
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
NCT01082926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 17 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Gliosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Gliosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Gliosarcoma page
35 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Gliosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Gliosarcoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Gliosarcoma condition card totals 35 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.